Explore
Multimodality Treatments in Metastatic Gastric Cancer
0 Ungluers have
Faved this Work
Login to Fave
Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 50 times via unglue.it ebook links.
- 50 - pdf (CC BY) at Unglue.it.
Keywords
- advanced gastric cancer
- biomarkers
- Body Composition
- bone flare
- CAR T cell therapy
- cfDNA
- circulating tumor cell
- conversion surgery
- ctDNA
- epithelial–mesenchymal transition
- Epstein Barr virus
- exome sequencing
- formalin fixed paraffin embedded
- gastric cancer
- gastro-oesophageal cancer
- hepatectomy
- HER2-inhibition
- immune checkpoint inhibitors
- Immunotherapy
- Liquid Biopsy
- liver metastasis
- medicine
- metastatic
- metastatic gastric cancer
- microsatellite instability
- mutational concordance
- n/a
- new drug development
- nutritional status
- outcome
- precision medicine
- predictive biomarkers
- RANK-L
- resistance to treatment
- response monitoring
- Sarcopenia
- stage IV
- stage iv gastric cancer
- subcutaneous fat area
- target therapy
- Toxicity
- Treatment
- tumor mutational burden
- Vaccines
- VEGFR-inhibition
- visceral fat area
Links
DOI: 10.3390/books978-3-0365-2593-8Editions